Keros Therapeutics Inc (KROS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2019 | 06-2019 | 03-2019 | |
| Cash Flows From Operating Activities | |||
| Net Income | -9,585 | -6,036 | -3,183 |
| Depreciation Amortization | 149 | 94 | 45 |
| Accounts payable and accrued liabilities | 1,442 | 596 | 813 |
| Other Working Capital | -3,033 | -2,965 | -39 |
| Other Operating Activity | 527 | 766 | -149 |
| Operating Cash Flow | $-10,500 | $-7,545 | $-2,513 |
| Cash Flows From Investing Activities | |||
| PPE Investments | -253 | -171 | N/A |
| Investing Cash Flow | $-253 | $-171 | $N/A |
| Cash Flows From Financing Activities | |||
| Common Stock Issued | 10 | 4 | N/A |
| Financing Cash Flow | $10 | $4 | $N/A |
| Beginning Cash Position | 23,390 | 23,390 | 23,390 |
| End Cash Position | 12,647 | 15,678 | 20,877 |
| Net Cash Flow | $-10,743 | $-7,712 | $-2,513 |
| Free Cash Flow | |||
| Operating Cash Flow | -10,500 | -7,545 | -2,513 |
| Capital Expenditure | -253 | -171 | N/A |
| Free Cash Flow | -10,753 | -7,716 | -2,513 |